Cantor Fitzgerald, Inc.: The PTC Therapeutics (PTCT.US) rating was reaffirmed, and the target price was 45.00 US dollars.
坎托菲茨杰拉德公司：重申PTC Therapeutics(PTCT.US)评级，由增持调整至增持评级, 目标价45.00美元。
Cantor Fitzgerald, Inc.: The PTC Therapeutics (PTCT.US) rating was reaffirmed, and the target price was 45.00 US dollars.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.